PARP inhibitors as monotherapy were assessed among germline BRCA1/2-mutated ovarian cancer patients with olaparib (NCT01078662) [35], which showed durable response rates regardless of platinum sensitivity. This evidence concerns the gene BRCA1 and ovarian carcinoma.